Annexure I

GlaxoSmithKline Consumer Healthcare Ltd.
24-25 Floor, One Horizon Center
Sector 43, DLF Phase 5, Golf Course Road
Gurugram (Haryana), India - 122002

T +91 124 4336500
F +91 124 4336600
E contact.4.gsk@gsk.com
www.gsk.com

The financial details and capital evolution of the transferor company for the previous 3 years and Half year ended September 30, 2018

Name of the Company: GlaxoSmithKline Consumer Healthcare Limited

(Rs. in Crores)

Description	As per last Audited Financial Year (Note 1)	1 year prior to the last Audited Financial Year (Note 1)	2 years prior to the last Audited Financial Year (Note 1)	Half year ended September 30, 2018 (Note 1) (Unaudited)
	2017-18	2016-17	2015-16	
Equity Paid up Capital	42.06	42.06	42.06	42.06
Reserves and surplus	3,443.06	3,080.61	2,403.58	3,549.17
Carry forward losses	-	-	-	-
Net Worth	3,485.12	3,122.67	2,445.63	3,591.23
Miscellaneous Expenditure	-	-	-	-
Secured Loans (Note 2)	-	8.36	-	-
Unsecured Loans	-	-	-	-
Fixed Assets	513.78	545.10	537.36	492.67
Income from Operations	4,377.05	4,421.09	4,308.73	2,379.13
Total Income	4,634.46	4,664.97	4,587.47	2,564.59
Total Expenditure	3,560.10	3,654.55	3,532.07	1,825.31
Profit before Tax	1,074.36	1,010.42	1,055.40	739.28
Profit after Tax	700.10	656.68	6,86.92	475.93
Cash profit (Note 3)	723.04	622.49	5,72.35	NA#
EPS	166.47	156.15	163.34	113.16
Book value per share	828.69	742.51	581.52	853.93

Notes:-

1. Financials for FY 2017-18, 2016-17 and half year ended September 2018 are as per Ind AS and FY 2015-16 is as per IGAAP.
2. Company had no loans/borrowings from Banks/financial institutions. Secured loans in FY 2016-17 represents finance lease obligations.
3. Cash profit denotes net cash flow from operating activities as per cash flow statement

Cash profit is not part of unaudited financial results submitted for half year ended September 30, 2018.

For **GlaxoSmithKline Consumer Healthcare Limited**

Vivek Anand
(Chief Financial Officer)

GlaxoSmithKline Consumer Healthcare Ltd.

CIN: L24231PB1958PLC002257
Registered Office
Patiala Road
Nabha (Punjab), India 147201

Hindustan Unilever Limited

Hindustan Unilever Limited
Unilever House
B D Sawant Marg
Chakala, Andheri East
Mumbai 400 099

Tel: +91 (22) 3983 0000
Web: www.hul.co.in
CIN: L15140MH1933PLC002030

The financial details and capital evolution of the transferee/resulting and transferor/demerged companies for the previous 3 years as per the audited statement of Accounts:
Name of the Company: Hindustan Unilever Limited

(Rs. in Crores)

	Limited Review (Unaudited Financials for the six months ended 30th September, 2018	As per last Audited Financial Year	1 year prior to the last Audited Financial Year	2 years prior to the last Audited Financial Year *(Pre-IND AS Financials)*
		2017-18	2016-17	2015-16
Equity Paid up Capital	216	216	216	216
Reserves and surplus	6,788	6,859	6,274	3,471
Carry forward losses	NIL	NIL	NIL	NIL
Net Worth^	6,990	7,061	6,476	3,673
Miscellaneous Expenditure	NIL	NIL	NIL	NIL
Secured Loans	NIL	NIL	NIL	NIL
Unsecured Loans	NIL	NIL	NIL	NIL
Fixed Assets*	4,663	4,572	4,227	3,301
Income from Operations	18,721	35,218	34,487	31,987
Total Income	19,161	35,787	35,013	32,488
Total Expenditure**	14,816	28,502	28,617	26,617
Profit before Tax	4,345	7,285	6,396	5,871
Profit after Tax	3,054	5,237	4,490	4,082
Cash profit#	N/A##	5,097	4,287	4,067
EPS (In Rs.)	14.11	24.20	20.75	18.87
Book value (In Rs.)	32.36	32.69	29.99	17.04

^ As per section 2(57) of the Companies Act, 2013
*Fixed Assets includes Intangible assets, Capital work-in-progress and Goodwill.
**Total Expenditure includes exceptional items.
Cash generated from Operations after taxes.
##It is not part of financial results submitted for quarter and half year ended 30th September, 2018

Hindustan Unilever Limited Mumbai

Note: The financials should <u>not be more than 6 months old</u>. In such cases additional column may be added to provide the latest financials.

Please note that for existing Listed Company, provide the last Annual Report and the audited / unaudited financials of the latest quarter (were it is due) accompanied mandatorily by the Limited Review Report of the auditor.

Annexure I (1)

Deloitte Haskins & Sells LLP

Chartered Accountants
7th Floor, Building 10, Tower B
DLF Cyber City Complex
DLF City Phase - II
Gurugram - 122 002
Haryana, India

Tel: +91 124 679 2000
Fax: +91 124 679 2012

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF
GlaxoSmithKline Consumer Healthcare Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **GlaxoSmithKline Consumer Healthcare Limited** ("the Company"), for the quarter and half year ended September 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

   This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Manjula Banerji
Partner
(Membership No. 086423)

Gurugram, November 1, 2018

GlaxoSmithKline Consumer Healthcare Ltd.

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED
Regd. Office: Patiala Road, Nabha - 147 201 (Punjab).
Head Office: 24th Floor, One Horizon Centre, DLF Phase 5, Golf Course Road, Gurugram- 122 002, Haryana.
Tel. No. 01765-306400; Fax No. 01765-220642

CIN: L24231PB1958PLC002257
Email ID: investor.2.co@gsk.com
Website: www.gsk-ch.in

(Rs. in Lakhs)

Statement of Unaudited Financial Results for the quarter and half year ended September 30, 2018

	Particulars	For the quarter ended			For the half year ended		For the year ended
		30/09/2018	30/06/2018	30/09/2017	30/09/2018	30/09/2017	31/03/2018
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
1	Income						
	(a) Revenue from operations	12,71,99	11,07,14	11,11,71	23,79,13	21,58,12	43,77,05
	(b) Other income	89,01	96,45	57,41	1,85,46	1,12,58	2,57,41
	Total Income	13,61,00	12,03,59	11,69,12	25,64,59	22,70,70	46,34,46
2	Expenses						
	(a) Cost of materials consumed	3,50,10	3,09,08	3,05,59	6,59,18	6,22,35	12,51,96
	(b) Purchase of stock-in-trade	29,17	24,88	42,26	54,05	72,15	1,39,64
	(c) Changes in inventories of work-in-progress, stock-in-trade and finished goods	6,64	2,90	46,09	9,54	42,05	40,98
	(d) Excise duty	-	-	-	-	60,54	60,54
	(e) Employee benefits expense	1,55,10	1,67,97	1,27,18	3,23,07	2,58,38	5,27,73
	(f) Depreciation and amortisation expense	15,07	14,70	17,68	29,77	34,69	64,37
	(g) Other expenses						
	(i) Advertising and promotion	1,32,60	1,43,89	1,35,94	2,76,49	2,63,78	5,46,73
	(ii) Others	2,44,71	2,28,13	1,95,73	4,72,84	4,13,08	9,26,12
	(h) Finance costs	19	18	55	37	1,09	2,03
	Total Expenses	9,33,58	8,91,73	8,71,02	18,25,31	17,68,11	35,60,10
3	Profit before tax (1-2)	4,27,42	3,11,86	2,98,10	7,39,28	5,02,59	10,74,36
4	Income tax expense						
	(a) Current tax	1,50,97	1,13,83	1,02,60	2,64,80	1,72,48	3,61,91
	(b) Deferred tax	96	(2,41)	3,09	(1,45)	5,48	12,35
	Total tax expense	1,51,93	1,11,42	1,05,69	2,63,35	1,77,96	3,74,26
5	Profit for the period (3-4)	2,75,49	2,00,44	1,92,41	4,75,93	3,24,63	7,00,10
6	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss						
	Remeasurements of post-employment benefit obligations	10,05	6,00	9,88	16,05	9,88	25,49
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(3,50)	(2,10)	(3,42)	(5,60)	(3,42)	(8,82)
	Total other comprehensive income, net of income tax	6,55	3,90	6,46	10,45	6,46	16,67
7	Total comprehensive income for the period (5+6)	2,82,04	2,04,34	1,98,87	4,86,38	3,31,09	7,16,77
8	Paid up equity share capital	42,06	42,06	42,06	42,06	42,06	42,06
	(Face value of Equity Shares)	10	10	10	10	10	10
9	Earnings per share (of Rs 10/- each) (not annualised):						
	(a) Basic	65.50	47.66	45.75	113.16	77.18	166.47
	(b) Diluted	65.50	47.66	45.75	113.16	77.18	166.47

Deloitte Haskins & Sells LLP Chartered Accountants

GlaxoSmithKline Consumer Healthcare Ltd.

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED
Regd. Office: Patiala Road, Nabha - 147 201 (Punjab).
Head Office: 24th Floor, One Horizon Centre, DLF Phase 5, Golf Course Road, Gurugram-122 002, Haryana.
Tel. No. 01765-306400; Fax No. 01765-220642

CIN: L24231PB1958PLC002257
Email ID: investor.2.co@gsk.com
Website: www.gsk-ch.in

(Rs. in Lakhs)

Statement of assets and liabilities		
Particulars	As at September 30, 2018	As at March 31, 2018
	UNAUDITED	AUDITED
ASSETS		
Non-current assets		
Property, plant and equipment	4,82,18	4,75,38
Capital work-in-progress	6,28	35,71
Intangible assets	7	15
Intangible assets under development	4,14	2,54
Financial assets		
i. Loans	12,42	16,28
ii. Other financial assets	21,54	21,71
Deferred tax assets (net)	1,16,91	1,15,45
Income tax assets (net)	64,65	1,77,91
Other non-current assets	4,60	5,53
Total non-current assets	**7,12,79**	**8,50,66**
Current assets		
Inventories	3,86,12	4,09,42
Financial assets		
i. Trade receivables	3,38,10	2,78,72
ii. Cash and cash equivalents	6,13,02	6,14,10
iii. Bank balances other than (ii) above	32,41,79	29,71,09
iv. Loans	12,02	14,80
v. Other financial assets	1,86,01	1,77,66
Employee Benefits	26,24	15,83
Other current assets	67,38	80,38
Total current assets	**48,70,68**	**45,62,00**
Total assets	**55,83,47**	**54,12,66**
EQUITY AND LIABILITIES		
Equity		
Equity share capital	42,06	42,06
Other equity	35,49,17	34,43,06
Total equity	**35,91,23**	**34,85,12**
LIABILITIES		
Non-current liabilities		
Provisions	1,19,84	1,25,41
Employee benefit obligations	64,90	59,54
Total non-current liabilities	**1,84,74**	**1,84,95**
Current liabilities		
Financial Liabilities		
(i) Trade payables	10,09,29	10,34,73
(ii) Other financial liabilities	3,82,82	3,11,09
Provisions	2,95,53	2,77,59
Employee benefit obligations	50,98	36,79
Other current liabilities	68,88	82,39
Total current liabilities	**18,07,50**	**17,42,59**
Total liabilities	**19,92,24**	**19,27,54**
Total equity and liabilities	**55,83,47**	**54,12,66**

Deloitte Haskins & Sells LLP Chartered Accountants

GlaxoSmithKline Consumer Healthcare Ltd.

Notes to the financial results:

1. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meeting held on November 01, 2018 and were subjected to a Limited review by the statutory auditors.

2. The above results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard (Ind AS) -34, "Interim Financial reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3. Effective April 01, 2018, the Company has adopted Ind AS 115 'Revenue from Contracts with Customers'. The application of Ind AS 115 did not have any material impact on the financial results of the Company.

4. Consequent to introduction of Goods and Services Tax (GST) with effect from July 01, 2017, Central Excise, Value Added Tax (VAT) etc. have been subsumed into GST. In accordance with Indian Accounting Standard, as applicable and Schedule III of the Companies Act, 2013, unlike Excise Duties, levies like GST, VAT, etc. are not part of Revenue. Accordingly, the figures for the half year ended September 2017 are not strictly relatable to current period numbers.

5. As the Company's business activity falls within a single operating segment namely "Nutrition", the disclosure requirements of Ind AS 108 "Operating segment" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, are not applicable.

6. The figures for the previous periods have been reclassified/regrouped wherever required to confirm to the current periods presentation/ classification. These are not material and do not affect the previously reported net profit or equity.

ON BEHALF OF THE BOARD OF DIRECTORS

N. Saluja

Navneet Saluja
Managing Director
DIN: 2183350

Place: Gurugram
Date : November 01, 2018

Deloitte Haskins & Sells LLP
Chartered Accountants

GlaxoSmithKline Consumer Healthcare Ltd.

Hindustan Unilever Limited

Hindustan Unilever Limited
Unilever House
B D Sawant Marg
Chakala, Andheri East
Mumbai 400 099

Tel: +91 (22) 3983 0000
Web: www.hul.co.in
CIN: L15140MH1933PLC002030

12th October, 2018

Stock Code BSE: 500696
NSE: HINDUNILVR
ISIN: INE030A01027

BSE Limited,
Corporate Relationship Department,
2nd Floor, New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra – Kurla Complex,
Bandra (E),
Mumbai – 400 051

Dear Sir,

Sub: Outcome of the Board Meeting held on 12th October, 2018

This is further to our letter dated 1st October, 2018, intimating the date of Board Meeting for consideration of unaudited financial results for the quarter and half year ended 30th September, 2018. Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today have:

1. approved the unaudited financial results for the quarter and half year ended 30th September, 2018. We attach herewith a copy of the approved unaudited financial results along with the limited review report of the auditors. A copy of the Press Release issued in this regard is also attached herewith.

   We are arranging to publish these results in the newspapers as per Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. declared an Interim Dividend of Rs. 9/- per equity share of face value of Re. 1/- each for the financial year ending 31st March, 2019.The record date for the purpose of determining the entitlement of the shareholders for the interim dividend has been fixed as 26th October, 2018, and dividend will be paid to the shareholders on or after 1st November, 2018.

   We would like to highlight that Company had earlier intimated the Stock Exchanges, post consultation with the exchanges, vide its letter dated 1st October, 2018, that the record date for determining the entitlement for the aforesaid dividend was fixed as 22nd October, 2018.

GlaxoSmithKline Consumer Healthcare Ltd.

Hindustan Unilever Limited

However, in view of the intervening holiday and in compliance with the requirements of Listing Regulations, it has been decided to change the record date. Accordingly, the record date for payment of interim dividend has been fixed as 26th October, 2018.

3. The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, approved the appointment of Mr. Leo Puri as Independent Director on the Board of the Company with effect from 12th October, 2018. Mr. Puri, until recently, was the Managing Director of UTI Asset Management Company. A press release issued in this regard is also attached.

Please take the above information on record.

Thanking You.

Yours faithfully,
For Hindustan Unilever Limited

HINDUSTAN UNILEVER LIMITED MUMBAI

Dev Bajpai
Executive Director, Legal & Corporate Affairs
and Company Secreatry
DIN:00050516 / FCS: F3354
ALS

GlaxoSmithKline Consumer Healthcare Ltd.

HINDUSTAN UNILEVER LIMITED

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTH ENDED 30TH SEPTEMBER, 2018

(Rs in Crores)

Unaudited Results for the quarter ended 30th September		Unaudited Results for the quarter ended 30th June	Particulars	Unaudited Results for the six months ended 30th September		Audited Results for the year ended 31st March
2018	2017	2018		2018	2017	2018
			Revenue from operations			
9,138	8,199	9,356	Sale of products (including excise duty)	18,494	17,293	34,619
96	110	131	Other operating revenue	227	238	599
305	204	135	**Other Income**	440	317	569
9,539	**8,513**	**9,622**	**TOTAL INCOME**	**19,161**	**17,848**	**35,787**
			EXPENSES			
3,343	2,885	3,379	Cost of materials consumed	6,722	5,789	12,491
1,182	1,061	905	Purchases of stock-in-trade	2,087	2,189	3,812
(90)	(17)	80	Changes in inventories of finished goods (including stock-in-trade) and work-in-progress	(10)	35	(71)
-	-	-	Excise duty	-	693	693
438	435	442	Employee benefits expenses	880	854	1,745
7	6	7	Finance costs	14	12	20
130	115	127	Depreciation and amortisation expenses	257	229	478
			Other expenses			
1,106	1,023	1,153	Advertising and promotion	2,259	1,928	4,105
1,236	1,240	1,277	Others	2,513	2,495	5,167
7,352	**6,748**	**7,370**	**TOTAL EXPENSES**	**14,722**	**14,224**	**28,440**
2,187	**1,765**	**2,252**	**Profit before exceptional items and tax**	**4,439**	**3,624**	**7,347**
(35)	36	(59)	Exceptional items [net credit/ (charge)]	(94)	23	(62)
2,152	**1,801**	**2,193**	**Profit before tax**	**4,345**	**3,647**	**7,285**
			Tax expenses			
(677)	(537)	(656)	Current tax	(1,333)	(1,155)	(2,148)
50	12	(8)	Deferred tax credit/(charge)	42	67	100
1,525	**1,276**	**1,529**	**PROFIT FOR THE PERIOD (A)**	**3,054**	**2,559**	**5,237**
			OTHER COMPREHENSIVE INCOME			
			Items that will not be reclassified subsequently to profit or loss			
-	-	-	Remeasurements of the net defined benefit plans	-	-	(16)
-	-	-	Tax on above	-	-	5
			Items that will be reclassified subsequently to profit or loss			
(0)	1	(2)	Fair value of debt instruments through other comprehensive income	(2)	(2)	(2)
0	(0)	1	Tax on above	1	1	1
(0)	**1**	**(1)**	**OTHER COMPREHENSIVE INCOME FOR THE PERIOD (B)**	**(1)**	**(1)**	**(12)**
1,525	**1,277**	**1,528**	**TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (A+B)**	**3,053**	**2,558**	**5,225**
216	216	216	**Paid up Equity Share Capital (Face value Re. 1 per share)**	216	216	216
			Other Equity			6,859
			Earnings per equity share (Face value of Re. 1 each)			
7.04	5.90	7.06	Basic (in Rs.)	14.11	11.82	24.20
7.04	5.90	7.06	Diluted (in Rs.)	14.11	11.82	24.19

100

SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES

(Rs in Crores)

STANDALONE			Particulars	STANDALONE		
Unaudited Results for the quarter ended 30th September		Unaudited Results for the quarter ended 30th June		Unaudited Results for the six months ended 30th September		Audited Results for year ended 31st March
2018	2017	2018		2018	2017	2018
			Segment Revenue (Sales and Other operating income)			
3,080	2,739	3,146	- Home Care	6,226	5,786	11,629
4,316	3,910	4,407	- Beauty & Personal Care	8,723	8,278	16,464
1,704	1,526	1,785	- Foods & Refreshment	3,489	3,180	6,487
134	128	149	- Others (includes Exports, Infant & Feminine Care etc.)	283	272	624
9,234	**8,303**	**9,487**	**Total Segment Revenue**	**18,721**	**17,516**	**35,204**
			Segment Results			
492	383	602	- Home Care	1,094	831	1,694
1,115	948	1,162	- Beauty & Personal Care	2,277	2,027	4,100
288	231	334	- Foods & Refreshment	622	526	985
2	(6)	(2)	- Others (includes Exports, Infant & Feminine Care etc.)	-	(11)	(12)
1,897	**1,556**	**2,096**	**Total Segment Results**	**3,993**	**3,373**	**6,767**
(7)	(6)	(7)	Less: Finance Costs	(14)	(12)	(20)
262	251	104	Add/(Less): Finance Income and Other unallocable income net of unallocable expenditure	366	286	538
2,152	**1,801**	**2,193**	**Total Profit Before Tax**	**4,345**	**3,647**	**7,285**
			Segment Assets			
2,058	2,203	2,021	- Home Care	2,058	2,203	2,100
4,753	4,623	4,721	- Beauty & Personal Care	4,753	4,623	4,873
1,908	1,781	1,712	- Foods & Refreshment	1,908	1,781	1,936
140	157	141	- Others (includes Exports, Infant & Feminine Care etc.)	140	157	140
8,818	7,304	10,570	- Unallocable corporate assets	8,818	7,304	8,100
17,677	**16,068**	**19,165**	**Total Segment Assets**	**17,677**	**16,068**	**17,149**
			Segment Liabilities			
2,988	2,707	2,951	- Home Care	2,988	2,707	2,865
5,050	4,499	4,944	- Beauty & Personal Care	5,050	4,499	4,860
1,297	1,203	1,288	- Foods & Refreshment	1,297	1,203	1,330
63	82	60	- Others (includes Exports, Infant & Feminine Care etc.)	63	82	80
1,275	1,135	4,447	- Unallocable corporate liabilities	1,275	1,135	939
10,673	**9,626**	**13,690**	**Total Segment Liabilities**	**10,673**	**9,626**	**10,074**

Notes on Segment Information:

1. Segment Revenue, Results, Assets and Liabilities represent amounts identifiable to each of the segments. Other "unallocable income net of unallocable expenditure" mainly includes interest income, dividend income, income from current investments (net), expenses on common services not directly identifiable to individual segments, corporate expenses and unallocable exceptional items.

Segment Assets and Segment Liabilities are as at 30th September 2018, 30th June 2018, 31st March 2018 and 30th September 2017. Unallocable corporate assets less Unallocable corporate liabilities mainly represent investment of surplus funds and cash and bank balances.

2. Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification.

Registered Office : Unilever House, B.D. Sawant Marg, Chakala, Andheri East, Mumbai 400 099.
CIN: L15140MH1933PLC002030. Tel : +91 (22) 3983 0000.
Email: levercare.shareholder@unilever.com

HINDUSTAN UNILEVER LIMITED

UNAUDITED BALANCE SHEET AS AT 30TH SEPTEMBER, 2018

(Rs in Crores)

	Statement of Assets and Liabilities	As at 30th September, 2018	As at 31st March, 2018
A	**ASSETS**		
1	**Non-current assets**		
	Property, plant and equipment	3,769	3,776
	Capital work-in-progress	452	430
	Goodwill	36	0
	Other intangible assets	409	366
	Investments in subsidiaries, associates and joint ventures	254	254
	Financial assets		
	- Investments	2	2
	- Loans	443	404
	- Other financial assets	25	6
	Non-current tax assets (net)	545	439
	Deferred tax assets (net)	297	255
	Other non-current assets	105	78
	Total Non-current assets	**6,337**	**6,010**
2	**Current assets**		
	Inventories	2,205	2,359
	Financial assets		
	- Investments	3,539	2,855
	- Trade receivables	1,093	1,147
	- Cash and cash equivalents	1,073	573
	- Bank balances other than cash and cash equivalents mentioned above	2,198	2,800
	- Other financial assets	728	829
	Other current assets	500	560
	Assets held for sale	4	18
	Total - Current assets	**11,340**	**11,139**
	TOTAL - ASSETS	**17,677**	**17,149**
B	**EQUITY AND LIABILITIES**		
1	**EQUITY**		
	Equity share capital	216	216
	Other equity	6,788	6,859
	Total - Equity	**7,004**	**7,075**
2	**LIABILITIES**		
	Non-current liabilities		
	Financial liabilities		
	- Other financial liabilities	136	115
	Provisions	817	772
	Non-current tax liabilities (net)	384	384
	Other non-current liabilities	195	167
	Total - Non-current liabilities	**1,532**	**1,438**
	Current liabilities		
	Financial liabilities		
	- Trade payables	7,324	7,013
	- Other financial liabilities	193	203
	Current tax liabilities (net)	300	-
	Other current liabilities	621	769
	Provisions	703	651
	Total - Current liabilities	**9,141**	**8,636**
	TOTAL - EQUITY AND LIABILITIES	**17,677**	**17,149**

Chartered Accountants

Glaxosmithkline Consumer Healthcare Ltd.

HINDUSTAN UNILEVER LTD. MUMBAI

Notes:

1. Sales grew by 11% during the quarter. Domestic Consumer sales grew by 12% during the quarter.

2. In compliance with IND AS 20 on Government Grants and consequent to clarifications published by The Institute of Chartered Accountants of India, the amount of budgetary support under GST (Goods and Service Tax) in relation to the existing eligible units under the different Industrial Promotion Schemes have been recognised as "Other Income" with effect from July 2018. In earlier periods these refunds were reported under "Other Operating Revenue" in the Statement of Profit and Loss. This has no impact on reported Profit Before Tax (PBT).

3. Earnings before interest, tax, depreciation and amortization (EBITDA) for the quarter at Rs. 2,019 crores (SQ 17: Rs. 1,682 crores) grew by 20%. EBITDA margin improvement is 160 bps vs SQ 17.

4. Profit After Tax before Exceptional Items for the quarter at Rs 1,522 crores (SQ 17: Rs 1,236 crores) grew by 23%.

5. Exceptional items, net cost in SQ 18 includes restructuring expenses Rs. 34 crores (SQ 17: Rs.10 crores), acquisition related cost Rs.1 crore (SQ 17: Rs. Nil) and profit from sale of equity shares in Kimberly Clark Lever Pvt. Ltd Rs. Nil (SQ 17: Rs. 46 crores).

6. Profit After Tax for the quarter at Rs. 1,525 crores (SQ 17: Rs.1,276 crores) grew by 20 %.

7. On 26th September, 2018 the Company completed the acquisition of ice-cream and frozen dessert business consisting of flagship brand 'Adityaa Milk' and front-end distribution network from Vijaykant Dairy and Food Products Limited (VDFPL) and its group company. The transaction is accounted as Business Combination as per Ind AS 103.

8. The Board has declared an interim dividend of Rs.9 per equity share of face value of Rs.1 each for the period ended 30th September, 2018 at its meeting held on 12th October, 2018. The record date for the purpose of determining the entitlement for payment of interim dividend is fixed as 26th October, 2018.

9. The Shareholders of the Company, had, at the Court Convened Meeting held on 30th June, 2016, approved the Scheme of Arrangement for transfer of the balance of Rs. 2,187.33 crores standing to the credit of the General Reserves to the Profit and Loss Account. The Company had accordingly filed a petition for sanction of the Scheme of Arrangement with the Hon'ble High Court of Mumbai (jurisdiction later changed to National Company Law Tribunal (NCLT). The Hon'ble National Company Law Tribunal, Mumbai Bench, vide it's order dated 30th August, 2018, has sanctioned the aforesaid Scheme of Arrangement. The Company has received the said Order on 27th September, 2018 and filed the Order and the Scheme with Registrar of Companies (ROC) on 5th October, 2018. Upon the Scheme becoming effective and subsequent to the reclassification of the amounts standing to the credit of the General Reserves to Profit and Loss account in the December Quarter, 2018, the amount so credited shall be paid out to the members of the Company, from time to time , by the Board of Directors at its sole discretion, in such manner, quantum and at such time as the Board may decide.

10. Previous period figures have been re-grouped/re-classified wherever necessary.

11. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12th October, 2018.

B S R & Co. LLP * Chartered Accountants *

GlaxoSmithKline Consumer Healthcare Ltd.

HINDUSTAN UNILEVER LTD. MUMBAI

12. The text of the above statement was approved by the Board of Directors at their meeting held on 12th October, 2018. The statutory auditors have expressed an unqualified report on the above results.

For more details on Results, visit Investor Relations section of our website at http://www.hul.co.in and Financial Results under Corporates section of www.nseindia.com and www.bseindia.com.

By order of the Board

Place: Mumbai
Date: 12th October, 2018

Sanjiv Mehta
Chairman and Managing Director
[DIN: 06699923]

HINDUSTAN UNILEVER LTD. MUMBAI

Glaxo Consumer Healthcare Ltd.

B S R & Co. LLP
Chartered Accountants

5th Floor, Lodha Excelus,
Apollo Mills Compound
N. M. Joshi Marg, Mahalaxmi
Mumbai - 400 011
India

Telephone +91 (22) 4345 5300
Fax +91 (22) 4345 5399

Limited Review Report on Quarterly Unaudited Financial Results of Hindustan Unilever Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of Hindustan Unilever Limited

We have reviewed the accompanying statement of unaudited financial results of Hindustan Unilever Limited ('the Company') for the quarter ended 30 September 2018 and the year-to-date results for the period from 1 April 2018 to 30 September 2018 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* specified under Section 143(10) of the Companies Act, 2013. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.: 101248W/W-100022

Akeel Master
Partner
Membership No. 046768

Mumbai
12 October 2018

GlaxoSmithKline Consumer Healthcare Ltd.

Hindustan Unilever Limited

RESULTS FOR THE QUARTER ENDING 30th SEPTEMBER 2018

12% DOMESTIC CONSUMER GROWTH, 10% UNDERLYING VOLUME GROWTH

Mumbai, October 12th, 2018: Hindustan Unilever Limited announced its results for the quarter ending 30th September 2018.

Domestic Consumer Growth was 12% with Underlying Volume Growth at 10%. EBITDA margin was up 160 bps and Profit after tax (bei) at Rs.1522 Crores grew by 23%.

Home Care: Strong volume driven growth sustained

Stellar performance in Home Care continued with Fabric wash and Household care delivering double-digit growth. Domex 'Pick up the Brush' campaign was launched in South India and was well received. Our market development and premiumization initiatives are delivering good results.

Beauty & Personal Care: Broad-based growth across Personal Wash and Personal Products

Skin Care delivered good performance with our key brands registering robust growths. Men's Fair and Lovely relaunch was well received. Hair Care witnessed strong double-digit growth and TRESemmé was relaunched with superior fragrance and packaging. Colour cosmetics delivered yet another quarter of strong performance on the back of successful innovations; "Kareena Kapoor Khan by Lakmé Absolute" an exclusive makeup range was also launched during the quarter. Axe Ticket has performed well and is continuing to gain traction. Personal Wash saw robust growth across the premium portfolio with Dove and Pears performing well.

Foods & Refreshment: Robust growth across categories

Beverages delivered broad based double-digit growth for the quarter enabled by flawless execution of our WiMI strategy. Ice Cream and Frozen desserts and Foods performed well with double-digit growths. We acquired Adityaa Milk Ice cream during the quarter and the integration has commenced.

Margin improvement sustained: EBITDA margin up by 160 bps

Our well-established savings programme and leverage in other expenses has enabled us to mitigate material inflation and drive margin improvement. Earnings before interest, tax, depreciation and amortization (EBITDA) at Rs. 2019 Crores was up by 20%. Profit after tax (PAT), at Rs. 1525 Crores was up by 20%.

The Board of Directors has declared an interim dividend of Rs. 9 per share for the year ending 31st March 2019.

Sanjiv Mehta, Chairman and Managing Director commented: "We have delivered another strong performance in the quarter and also for the half year. Our focus on strengthening the core, leading market development and driving excellence in execution has enabled us to deliver competitive and profitable growth.

In the near term, we expect demand to be stable. Our strength of agility and responsiveness gives us confidence to navigate the headwinds arising from crude inflation and currency depreciation. Our strategic agenda remains one of delivering Consistent, Competitive, Profitable and Responsible growth."

Glaxo Consumer Healthcare Ltd.

Hindustan Unilever Limited

Leo Puri Appointed as Independent Director on the HUL Board

Mumbai, October 12, 2018: Hindustan Unilever Limited (HUL) today announced the appointment of Mr. Leo Puri (57), as an Independent Director on its Board effective October 12, 2018.

Mr. Puri, until recently, was the Managing Director of UTI Asset Management Company. He has also previously served as an Independent Director in companies including Max New York Life Insurance Company, Infosys, Bennett Coleman & Co.

Prior to joining UTI Asset Management Company as CEO in August 2013, Mr. Puri was Director at McKinsey & Company until 2007, and has also been a Senior Advisor to the Firm. He was a Managing Director at Warburg Pincus, a leading Private Equity Firm, from 2007 to 2011. Earlier in his career he worked in the UK, US and Singapore with A.T. Kearney, Spicer & Oppenheim and Lloyds Bank.

Welcoming Mr. Puri's appointment, Mr. Sanjiv Mehta, Chairman & MD, HUL said, "Leo has a great track record of strategic leadership and transformation engagements across local and global markets. His experience and expertise across private and public institutions will be an excellent complement to our Board."

Mr. Puri stated that "HUL is an iconic institution and one of the most well-respected companies in the country. I am delighted to join the Board and look forward to contributing as an Independent Director."

+++

About Hindustan Unilever Limited

Hindustan Unilever Limited (HUL) is India's largest Fast Moving Consumer Goods company with its products touching the lives of nine out of ten households in India. HUL works to create a better future every day.

For media enquiries:
mediacentre.hul@unilever.com

GlaxoSmithKline Consumer Healthcare Ltd.